{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:45:14Z","timestamp":1790876714535,"version":"4.1.0"},"reference-count":79,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Diabetic neuropathy is one of the most common complications of diabetes. This complication is peripheral neuropathy with predominant sensory impairment, and its symptoms begin with hyperesthesia and pain and gradually become hypoesthesia with the loss of nerve fibers. In some cases, lower limb amputation occurs when hypoalgesia makes it impossible to be aware of trauma or mechanical stimuli. On the other hand, up to 50% of these complications are asymptomatic and tend to delay early detection. Therefore, sensitive and reliable biomarkers for diabetic neuropathy are needed for an early diagnosis of this condition. This review focuses on systemic biomarkers that may be useful at this time. It also describes research on the relationship between target gene polymorphisms and pathological conditions. Finally, we also introduce current information on regenerative therapy, which is expected to be a therapeutic approach when the pathological condition has progressed and nerve degeneration has been completed.<\/jats:p>","DOI":"10.3390\/ijms22052301","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T02:08:17Z","timestamp":1614305297000},"page":"2301","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Recent Advances in Biomarkers and Regenerative Medicine for Diabetic Neuropathy"],"prefix":"10.3390","volume":"22","author":[{"given":"Yoshikai","family":"Fujita","sequence":"first","affiliation":[{"name":"Division of Pharmaceutics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7851-6822","authenticated-orcid":false,"given":"Tatsufumi","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic neuropathy","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic Neuropathy: A Position Statement by the American Diabetes Association","volume":"40","author":"Boulton","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"The Diabetes Control and Complications Trial Research Group (1993). The effect of intenstreatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 329, 977\u2013986.","DOI":"10.1056\/NEJM199309303291401"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2337\/diacare.29.02.06.dc05-1549","article-title":"Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion","volume":"29","author":"Martin","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0168-8227(99)00112-6","article-title":"Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life","volume":"47","author":"Galer","year":"2000","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/bs.irn.2016.03.006","article-title":"Glucotoxic Mechanisms and related therapeutic approaches","volume":"127","author":"Yagihashi","year":"2016","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gasecka, A., Siwik, D., Gajewska, M., Jaguszewski, M.J., Mazurek, T., Filipiak, K.J., Postu\u0142a, M., and Eyileten, C. (2020). Early biomarkers of neurodegenerative and neurovascular disorders in diabetes. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092807"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1210\/er.2018-00107","article-title":"Emerging biomarkers, tools, and treatments for diabetic polyneuropathy","volume":"40","author":"Herder","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"558758","DOI":"10.3389\/fneur.2020.558758","article-title":"Emerging roles of microRNAs as biomarkers and therapeutic targets for diabetic Neuropathy","volume":"11","author":"Fan","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1007\/s001250050839","article-title":"Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct","volume":"40","author":"Sugimoto","year":"1997","journal-title":"Diabetologia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2174\/138161208784139774","article-title":"Role of advanced glycation end products in diabetic neuropathy","volume":"14","author":"Sugimoto","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.2337\/db09-0320","article-title":"Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes","volume":"58","author":"Dobler","year":"2009","journal-title":"Diabetes"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1172\/JCI18058","article-title":"Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily","volume":"114","author":"Bierhaus","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0074-7742(02)50072-6","article-title":"Glycation in diabetic neuropathy: Characteristics, consequences, causes, and therapeutic options","volume":"50","author":"Thornalley","year":"2002","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/nm.2750","article-title":"Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy","volume":"18","author":"Bierhaus","year":"2012","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Andersson, D.A., Gentry, C., Light, E., Vastani, N., Vallortigara, J., Bierhaus, A., Fleming, T., and Bevan, S. (2013). Methylglyoxal evokes pain by stimulating TRPA1. PLoS ONE, 8.","DOI":"10.1371\/annotation\/e707d50a-13b3-4cc3-b507-7d8360d8f048"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1097\/j.pain.0000000000001644","article-title":"Methylglyoxal causes pain and hyperalgesia in human through C-fiber activation","volume":"160","author":"Riegel","year":"2019","journal-title":"Pain"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.7150\/thno.36077","article-title":"The role of Na(v)1.7 and methylglyoxal-mediated activation of TRPA1 in itch and hypoalgesia in a murine model of type 1 diabetes","volume":"9","author":"Cheng","year":"2019","journal-title":"Theranostics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/dme.12753","article-title":"The role of serum methylglyoxal on diabetic peripheral and cardiovascular autonomic neuropathy: The ADDITION Denmark study","volume":"32","author":"Hansen","year":"2015","journal-title":"Diabet. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2337\/dc17-2062","article-title":"Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark","volume":"41","author":"Andersen","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1042\/bst0311343","article-title":"Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation","volume":"31","author":"Thornalley","year":"2003","journal-title":"Biochem. Soc. Trans."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.expneurol.2011.12.015","article-title":"Protection from diabetes-induced peripheral sensory neuropathy--a role for elevated glyoxalase I?","volume":"234","author":"Jack","year":"2012","journal-title":"Exp. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.gene.2012.11.009","article-title":"Identification of glyoxalase I polymorphisms associated with enzyme activity","volume":"515","author":"Peculis","year":"2013","journal-title":"Gene"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jdiacomp.2012.12.002","article-title":"Association of reduced glyoxalase I activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients","volume":"27","author":"Skapare","year":"2013","journal-title":"J. Diabetes Complicat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1055\/s-0033-1345124","article-title":"C332C genotype of glyoxalase I and its association with late diabetic complications","volume":"121","author":"Groener","year":"2013","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2006.12.002","article-title":"Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors","volume":"19","author":"Miyake","year":"2007","journal-title":"Semin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"172975","DOI":"10.1016\/j.ejphar.2020.172975","article-title":"Toll-like receptor 4: A promising crossroads in the diagnosis and treatment of several pathologies","volume":"874","author":"Garcia","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1471-4159.2007.05050.x","article-title":"Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats","volume":"104","author":"Yamagishi","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"112967","DOI":"10.1016\/j.expneurol.2019.112967","article-title":"Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease?","volume":"320","author":"Elzinga","year":"2019","journal-title":"Exp. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neulet.2014.11.020","article-title":"Toll-like receptor 4 and tumor necrosis factor-alpha as diagnostic biomarkers for diabetic peripheral neuropathy","volume":"585","author":"Zhu","year":"2015","journal-title":"Neurosci. Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.dsx.2013.02.005","article-title":"Serum levels of TNF-\u03b1 in peripheral neuropathy patients and its correlation with nerve conduction velocity in type 2 diabetes mellitus","volume":"7","author":"Hussain","year":"2013","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Long, H., O\u2019Connor, B.P., Zemans, R.L., Zhou, X., Yang, I.V., and Schwartz, D.A. (2014). The Toll-like receptor 4 polymorphism Asp299Gly but not Thr399Ile influences TLR4 signaling and function. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0093550"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2337\/diacare.27.1.179","article-title":"Asp299Gly and Thr399Ilegenotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes","volume":"27","author":"Rudofsky","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.diabres.2016.04.002","article-title":"The effect of Toll-like receptor 4 gene polymorphism on vascular complications in type 2 diabetes patients","volume":"116","author":"Buraczynska","year":"2016","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2019.10.021","article-title":"Adiponectin, a unique adipocyte-derived factor beyond hormones","volume":"292","author":"Maeda","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jdiacomp.2015.11.004","article-title":"Association between circulating adipocytokine concentrations and microvascular complications in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of controlled cross-sectional studies","volume":"30","author":"Rodriguez","year":"2016","journal-title":"J. Diabetes Complicat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clinbiochem.2014.10.009","article-title":"Association of serum adiponectin with diabetic microvascular complications among south Indian type 2 diabetic subjects\u2014(CURES-133)","volume":"48","author":"Pradeepa","year":"2015","journal-title":"Clin. Biochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2337\/dc16-2259","article-title":"Proinflammatory cytokines predict the incidence and progression of distal sensorimotor polyneuropathy: KORA F4\/FF4 Study","volume":"40","author":"Herder","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.freeradbiomed.2013.06.009","article-title":"MicroRNAs: Potential mediators and biomarkers of diabetic complications","volume":"64","author":"Kato","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Balde\u00f3n, R.L., Weigelt, K., de Wit, H., Ozcan, B., van Oudenaren, A., Semp\u00e9rtegui, F., Sijbrands, E., Grosse, L., Freire, W., and Drexhage, H.A. (2014). Decreased serum level of miR-146a as sign of chronic inflammation in Type 2 diabetic patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115209"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.neuroscience.2013.11.057","article-title":"The role of miR-146a in dorsal root ganglia neurons of experimental diabetic peripheral neuropathy","volume":"259","author":"Wang","year":"2014","journal-title":"Neuroscience"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2019.03.008","article-title":"Post-transcriptional markers with clinical complications in Type 1 and Type 2 diabetes mellitus","volume":"490","author":"Massaro","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fendo.2019.00385","article-title":"Micro-RNAs 518d-3p and 618 are upregulated in individuals with Type 1 diabetes with multiple microvascular complications","volume":"10","author":"Santos","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/clinchem\/48.11.1931","article-title":"Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients","volume":"48","author":"Kulpav","year":"2002","journal-title":"Clin. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(82)91748-2","article-title":"Serum neuron-specific enolase: A marker for disease extent and response to therapy of small-cell lung cancer","volume":"1","author":"Carney","year":"1982","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0009-8981(82)90056-0","article-title":"High levels of immunoreactive nervous system-specific enolase in sera of patients with neuroblastoma","volume":"121","author":"Ishiguro","year":"1982","journal-title":"Clin. Chim. Acta"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.2337\/dc13-0590","article-title":"NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy","volume":"36","author":"Li","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.dsx.2020.06.065","article-title":"Effect of photobiomodulation on serum neuron specific enolase (NSE) among patients with diabetic peripheral neuropathy\u2014A pilot study","volume":"14","author":"Anju","year":"2020","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/sj.embor.7400114","article-title":"To move or not to move? Semaphorin signalling in cell migration","volume":"5","author":"Tamagnone","year":"2004","journal-title":"EMBO Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.tibs.2008.01.006","article-title":"Semaphorin signaling: Progress made and promises ahead","volume":"33","author":"Zhou","year":"2008","journal-title":"Trends Biochem. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrrheum.2017.201","article-title":"The role of semaphorins in immune responses and autoimmune rheumatic diseases","volume":"14","author":"Nishide","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0014-4886(03)00046-3","article-title":"Induction of neuropilins-1 and -2 and their ligands; Sema3A, Sema3F, and VEGF, during Wallerian degeneration in the peripheral nervous system","volume":"183","author":"Scarlato","year":"2003","journal-title":"Exp. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1023\/B:NERE.0000023602.72354.82","article-title":"Modulation of sciatic nerve expression of class 3 semaphorins by nerve injury","volume":"29","author":"Ara","year":"2004","journal-title":"Neurochem. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neures.2010.09.006","article-title":"Intrathecally administered Sema3A protein attenuates neuropathic pain behavior in rats with chronic constriction injury of the sciatic nerve","volume":"69","author":"Hayashi","year":"2011","journal-title":"Neurosci. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.mce.2017.11.025","article-title":"High glucose up-regulates Semaphorin 3A expression via the mTOR signaling pathway in keratinocytes: A potential mechanism and therapeutic target for diabetic small fiber neuropathy","volume":"472","author":"Wu","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0006-8993(94)90252-6","article-title":"Nerve growth factor administration protects against experimental diabetic sensory neuropathy","volume":"634","author":"Apfel","year":"1994","journal-title":"Brain Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.12659\/MSM.909449","article-title":"Diagnostic significance of serum levels of nerve growth factor and brain derived neurotrophic factor in diabetic peripheral neuropathy","volume":"24","author":"Sun","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1600-0404.1990.tb00984.x","article-title":"Low serum levels of nerve growth factor in diabetic neuropathy","volume":"81","author":"Faradji","year":"1990","journal-title":"Acta Neurol. Scand."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1464-5491.2009.02856.x","article-title":"Nerve growth factor and expression of its receptors in patients with diabetic neuropathy","volume":"26","author":"Kim","year":"2009","journal-title":"Diabet. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.2337\/diabetes.54.11.3288","article-title":"Apoptotic stress is counterbalanced by survival elements preventing programmed cell death of dorsal root ganglions in subacute type 1 diabetic BB\/Wor rats","volume":"54","author":"Kamiya","year":"2005","journal-title":"Diabetes"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0896-6273(02)00941-8","article-title":"Hsp27 upregulation and phosphorylation is required for injured sensory and motor neuron survival","volume":"36","author":"Benn","year":"2002","journal-title":"Neuron"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.2337\/dc13-1780","article-title":"HSP27 concentrations are lower in patients with type 1 diabetes and correlate with large nerve fiber dysfunction","volume":"37","author":"Pourhamidi","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1007\/s00125-011-2303-5","article-title":"Heat shock protein 27 is associated with better nerve function and fewer signs of neuropathy","volume":"54","author":"Pourhamidi","year":"2011","journal-title":"Diabetologia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.2337\/db08-0009","article-title":"Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: A novel circulating marker for diabetic neuropathy","volume":"57","author":"Gruden","year":"2008","journal-title":"Diabetes"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1172\/JCI12188","article-title":"Reversal of experimental diabetic neuropathy by VEGF gene transfer","volume":"107","author":"Schratzberger","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/diabetes.54.3.846","article-title":"Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats","volume":"54","author":"Kato","year":"2005","journal-title":"Diabetes"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2337\/db05-1160","article-title":"Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats","volume":"55","author":"Nakae","year":"2006","journal-title":"Diabetes"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ana.21675","article-title":"Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: A randomized, double-blinded trial","volume":"65","author":"Ropper","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2337\/db08-1526","article-title":"Engineered zinc finger protein-mediated VEGF-a activation restores deficient VEGF-a in sensory neurons in experimental diabetes","volume":"59","author":"Pawson","year":"2010","journal-title":"Diabetes"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2174\/1389450054021981","article-title":"Vascular endothelial growth factor and diabetic retinopathy: Role of oxidative stress","volume":"6","author":"Caldwell","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/jgm.893","article-title":"VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice","volume":"8","author":"Murakami","year":"2006","journal-title":"J. Gene Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.expneurol.2010.10.015","article-title":"Placental growth factor-2 gene transfer by electroporation restores diabetic sensory neuropathy in mice","volume":"227","author":"Murakami","year":"2011","journal-title":"Exp. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Naruse, K., Sato, J., Funakubo, M., Hata, M., Nakamura, N., Kobayashi, Y., Kamiya, H., Shibata, T., Kondo, M., and Himeno, T. (2011). Transplantation of bone marrow-derived mononuclear cells improves mechanical hyperalgesia; cold allodynia and nerve function in diabetic neuropathy. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027458"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.2337\/db08-0031","article-title":"Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats","volume":"57","author":"Shibata","year":"2008","journal-title":"Diabetes"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2337\/diabetes.54.6.1823","article-title":"Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy","volume":"54","author":"Naruse","year":"2005","journal-title":"Diabetes"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/1574889810666150702124059","article-title":"Exosome-based strategies for diagnosis and therapy","volume":"10","author":"Urbanelli","year":"2015","journal-title":"Recent Pat. CNS Drug Discov. Discontin."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/glia.22558","article-title":"Schwann cell-derived exosomes enhance axonal regeneration in the peripheral nervous system","volume":"61","author":"Picou","year":"2013","journal-title":"Glia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2337\/db19-0432","article-title":"Exosomes derived from Schwann cells ameliorate peripheral neuropathy in type 2 diabetic mice","volume":"69","author":"Wang","year":"2020","journal-title":"Diabetes"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00125-019-05043-0","article-title":"Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes","volume":"63","author":"Fan","year":"2020","journal-title":"Diabetologia"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2301\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:28:45Z","timestamp":1760160525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":79,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["ijms22052301"],"URL":"https:\/\/doi.org\/10.3390\/ijms22052301","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]}}}